Clonazepam half-life
Clonazepam labeling places the typical elimination half-life in a broad 30-to-40-hour range.
Every curve begins at 100%. No dose or measured body concentration is assumed.
X-axis: elapsed time. Y-axis: modeled percentage of the relative starting point remaining. This is a mathematical visualization, not a personal concentration estimate.
Clonazepam: evidence and interpretation notes
The number behind the long tail
Clonazepam labeling places the typical elimination half-life in a broad 30-to-40-hour range. The chart uses 34 hours as a readable center while retaining that variability beside it.
A 34-hour input gives this profile one auditable line for Clonazepam. The line deliberately stops short of claims about clinical effect, measured concentration, or testing results.
Clonazepam is a longer-acting benzodiazepine, so it is a useful contrast with shorter entries such as alprazolam or etizolam. Its curve declines slowly in the simple model.
The 34 hour input means one modeled half-life spans more than a day. That makes accumulation and residual exposure conceptually important, especially when doses repeat.
The entry cites a direct DailyMed label, a benzodiazepine pharmacology review, and the PubChem compound record.
The model does not estimate seizure control, anxiety relief, sedation, withdrawal risk, or functional impairment.
For Clonazepam, the most important reading habit is to separate elimination from clinical effect. A lower modeled amount does not prove that sedation, memory effects, coordination changes, or withdrawal risk have ended.
What each source contributes
- DailyMed: Clonazepam tablet. This product label adds formulation-specific pharmacokinetic context and does not represent every route or product.
- Griffin CE et al. Benzodiazepine pharmacology and central nervous system effects (2013). This supporting literature record adds compound-specific background and is used only within the limits of its design.
- PubChem: Clonazepam. This identity record confirms names and compound identity and does not supply a human half-life.
For Clonazepam, the numerical model is tied most closely to DailyMed: Clonazepam tablet. As a product label, it adds formulation-specific pharmacokinetic context; it does not represent every route or product.
Why there is no range on the chart
This profile plots 34 hours for Clonazepam without adding an unsourced high-low band. A single supported center is more honest than manufacturing a range from unrelated routes, populations, or formulations.
InterpretationReading the curve and its category context
Reading this curve
HalfLifeDB uses 34 h as a representative input for Clonazepam. In the simplified model, about 61.3% remains after 24 hours and about 3% remains after five half-lives, or roughly 7.1 days.
This is a day-scale half-life. Repeated exposure, timing, and source context start to matter more than a single snapshot of the curve. The curve is relative: it does not estimate a person's measured concentration, effects, impairment, or time to clearance.
benzodiazepine context
Benzodiazepine half-life estimates can be especially sensitive to active metabolites, redistribution, age, liver function, and repeated use.
- A long terminal half-life does not mean effects remain constant for the whole period.
- Shorter-acting entries can still have residual effects after the main subjective effects fade.
- Repeated exposure can create overlap that a single-dose curve does not show.
ComparisonTimeline checkpoints and nearby profiles
Clonazepam timeline checkpoints
| Elapsed time | Modeled remaining | Reading note |
|---|---|---|
| 24 h | 61.3% | Meaningful modeled decline, not near-zero |
| 3.0 days | 23.0% | Long-tail portion of the model |
| 5.0 days | 8.66% | Low modeled remainder, not a clearance guarantee |
| 7.0 days | 3.26% | Low modeled remainder, not a clearance guarantee |
| 14 days | 0.11% | Low modeled remainder, not a clearance guarantee |
Nearby profiles by half-life
These entries sit near Clonazepam within the benzodiazepine group when sorted by representative half-life. That makes them curve comparisons, not statements about equal potency, effects, or risk.
- Chlordiazepoxide (36 h)
- Diazepam (30 h)
- Lorazepam (14 h)
- Alprazolam (11.2 h)
EvidencePharmacokinetic inputs and source trail
Pharmacokinetics at a glance
| Representative half-life | 34 h |
|---|---|
| Curve type | Normalized, first-order decline |
Selection note: Clonazepam labeling places the typical elimination half-life in a broad 30-to-40-hour range. The chart uses 34 hours as a readable center while retaining that variability beside it.
Sources and evidence context
A linked record is not automatically proof of the displayed value. Study, labeling, review, and compound identity sources serve different purposes; notes below identify limitations when they are known.
- Official labeling DailyMed label: Clonazepam tablet.Official U.S. product labeling used for formulation and labeled pharmacokinetic context; its statements apply to the described product.
- Research abstract Griffin CE et al. Benzodiazepine pharmacology and central nervous system effects (2013).Supporting literature record. Its role and study design should be read from the linked source before applying any numerical finding.
- Identity record PubChem Compound Summary: Clonazepam.Compound identity and naming record. It supplies chemistry context, not independent numerical support for the model.
BoundariesWhat this page cannot answer and where to continue
What this page does not answer
- It does not estimate impairment, intoxication, or fitness to drive.
- It does not predict urine, blood, saliva, or hair test results.
- It does not model repeated exposure, tolerance, withdrawal, or interactions.
- It does not replace clinician, pharmacist, toxicologist, or emergency guidance.
Continue with context
- All substance profiles
- Browse the benzodiazepine group
- Compare this curve
- Clearance and volume of distribution
- Bioavailability, route, and formulation
- Active metabolites and parent compounds
- First-order vs nonlinear kinetics
- Detection windows vs half-life
- Reading labels and source quality
Read the medical disclaimer, methodology, and research standards before using the model for comparison.